Evidence map›Paper›PMID 31130739›Full record

ArticleElectrochimica acta2018

Integrating Electrochemical Immunosensing and Cell Adhesion Technologies for Cancer Cell Detection and Enumeration.

Rajesh Seenivasan, Jay W Warrick, Carlos I Rodriguez, William Mattison, David J Beebe, Vijayasaradhi Setaluri, Sundaram Gunasekaran

Abstract read
In one paragraph

Article in Electrochimica acta, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rajesh Seenivasan *Department of Biological Systems Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
Jay W Warrick *Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Carlos I RodriguezDepartment of Dermatology, UW School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
William MattisonDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
David J BeebeDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Vijayasaradhi SetaluriDepartment of Dermatology, UW School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
Sundaram GunasekaranDepartment of Biological Systems Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Skin Diseases Research Center at the University of WisconsinP30AR066524 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI WOOD, GARY S · 2014 to 2018
$2.6M
NCI NIH HHS P30 CA014520NIAMS NIH HHS P30 AR066524
6 · The paper itself

Abstract

We have successfully integrated techniques for controlling cell adhesion and performing electrochemical differential pulse voltammetry (DPV) through the use of digitally controlled microfluidics and patterned transparent indium tin oxide electrode arrays to enable rapid and sensitive enumeration of cancer cells in a scalable microscale format. This integrated approach leverages a dual-working electrode (WE) surface to improve the specificity of the detection system. Here, one of the WE surfaces is functionalized with anti-Melanocortin 1 Receptor antibodies specific to melanoma cancer cells, while the other WE acts as a control (i.e., without antibody), for detecting non-specific interactions between cells and the electrode. The method is described and shown to provide effective detection of melanoma cells at concentrations ranging between 25 to 300 cells per 20 μL sample volume after a 5 min incubation and 15 s of DPV measurements. The estimated limit of detection was ~17 cells. The sensitivity and specificity of the assay were quantified using addition of large fractions of non-target cells and resulted in a detection reproducibility of ~97%. The proposed approach demonstrates a unique integration of electrochemical sensing and microfluidic cell adhesion technologies with multiple advantages such as label-free detection, short detection times, and low sample volumes. Next steps for this platform include testing with patient samples and use of other cell-surface biomarkers for detection and enumeration of circulating tumor cells in prostate, breast, and colon cancer.

Indexed as

cancer cellsdifferential pulse voltammetrylabel-free detectionmicrofluidicspoint-of-care

Identifiers

PMID31130739
PMCPMC6530932
OpenAlexW2886438517

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.